SMLE gastroenterology questions

The urea breath test detects active infection by measuring labelled CO2 produced from urea hydrolysis by bacterial urease, with sensitivity and specificity above 95% when the patient has not recently used PPIs, bismuth, or antibiotics. Stool antigen testing has similar accuracy and is also acceptable, but serology only detects past exposure through IgG antibodies and remains positive even after successful eradication, making it unsuitable for confirming active infection or test-of-cure. Serum gastrin is used to evaluate gastrin-secreting tumours, not H. pylori status. The urea breath test is a noninvasive, guideline-preferred option for both initial diagnosis and confirming eradication.

• A. This is a syphilis screening test and unrelated to H. pylori diagnosis.
• B. Serology detects prior exposure via IgG antibodies and cannot distinguish active from past infection, so it stays positive after cure.
• D. Fasting gastrin evaluates for gastrinoma, not H. pylori infection.

Standard first-line triple therapy combines a proton pump inhibitor with two antibiotics, amoxicillin and clarithromycin, for 10-14 days. The PPI raises intragastric pH, which both promotes ulcer healing and improves antibiotic stability and efficacy against H. pylori. Amoxicillin inhibits bacterial cell wall synthesis, while clarithromycin inhibits the 50S ribosomal subunit, together achieving synergistic eradication rates above 80% in areas with low clarithromycin resistance. This regimen is recommended unless local clarithromycin resistance exceeds 15%, in which case bismuth-based quadruple therapy is preferred.

• A. Gentamicin is not used for H. pylori eradication and lacks appropriate oral bioavailability and gastric efficacy for this indication.
• B. Ciprofloxacin is not part of standard first-line therapy and metronidazole-based regimens are reserved for penicillin-allergic patients or as part of quadruple therapy.
• D. Ranitidine is a less potent acid suppressor than a PPI and azithromycin is not a standard component of eradication therapy.

Sudden severe abdominal pain, a rigid board-like abdomen with generalized peritonism, tachycardia, and free subdiaphragmatic air on an erect chest radiograph in a patient with known peptic ulcer disease are classic for perforation of a peptic ulcer leading to pneumoperitoneum. Free air outlines the diaphragm because gastric or duodenal contents leak into the peritoneal cavity through the perforation. This is a surgical emergency requiring resuscitation, broad-spectrum antibiotics, and urgent exploratory laparotomy or laparoscopic repair, often with an omental (Graham) patch. Acute pancreatitis and cholecystitis typically do not produce free subdiaphragmatic air, and mesenteric ischemia classically presents with pain out of proportion to examination findings rather than this degree of peritonism this acutely.

• A. Mesenteric ischemia classically presents with pain out of proportion to exam findings and does not typically show free air unless bowel infarction with perforation has occurred.
• B. Pancreatitis causes epigastric pain radiating to the back and elevated lipase, but does not typically produce free subdiaphragmatic air.
• D. Cholecystitis causes right upper quadrant pain and a positive Murphy sign, not generalized peritonism with pneumoperitoneum.

This presentation of multiple refractory peptic ulcers, diarrhea, markedly elevated fasting gastrin with low gastric pH strongly suggests Zollinger-Ellison syndrome caused by a gastrin-secreting neuroendocrine tumor (gastrinoma). The secretin stimulation test confirms the diagnosis: in normal individuals secretin suppresses gastrin release, but in gastrinoma, gastrin paradoxically rises further (typically more than 120 pg/mL above baseline) because tumor cells lack normal feedback inhibition. Once confirmed, imaging studies such as somatostatin receptor scintigraphy or endoscopic ultrasound localize the tumor, and patients should be screened for MEN1 syndrome. Esophageal pH monitoring assesses reflux, not gastrin-driven acid hypersecretion, and calcitonin and glucose tolerance tests evaluate unrelated endocrine conditions.

• B. This test screens for diabetes and is unrelated to the diagnosis of gastrinoma.
• C. Calcitonin is a tumor marker for medullary thyroid carcinoma, not gastrinoma.
• D. This test quantifies acid reflux into the esophagus and does not confirm a gastrin-secreting tumor.

In patients at increased risk of NSAID-induced ulcers, including those with a prior history of peptic ulcer disease, co-prescription of a proton pump inhibitor is the most effective strategy to reduce mucosal injury, as it maintains gastric pH at levels that promote healing and reduce acid-related damage despite continued prostaglandin inhibition by the NSAID. Enteric coating reduces direct contact injury but does not prevent the systemic prostaglandin-mediated mucosal damage that occurs regardless of the route of administration. Standard-dose H2-receptor antagonists are less effective than PPIs for prevention of NSAID-associated ulcers, particularly gastric ulcers. Taking NSAIDs with food may reduce dyspepsia but does not substantially lower the risk of ulceration or bleeding.

• B. Enteric coating reduces local gastric irritation but does not prevent the systemic prostaglandin-mediated injury responsible for most NSAID-induced ulcers.
• C. Taking NSAIDs with food may reduce dyspeptic symptoms but does not meaningfully reduce the risk of ulceration in high-risk patients.
• D. Standard-dose H2 blockers are inferior to PPIs for preventing NSAID-induced gastric ulcers, especially in high-risk patients.

A firm, non-tender, enlarged left supraclavicular lymph node, known as Virchow's node, is a classic sign of metastatic intra-abdominal malignancy, most commonly gastric cancer, and represents an alarm feature mandating urgent upper endoscopic evaluation regardless of other symptoms. While chronic H. pylori gastritis and a diet high in salted or smoked foods are established risk factors that increase the lifetime likelihood of developing gastric cancer, they are not themselves physical findings indicating that cancer is already present. Epigastric pain alone is nonspecific and common in many benign conditions. The combination of weight loss, early satiety, and a palpable Virchow's node in this patient should prompt urgent investigation for gastric malignancy.

• A. This is a dietary risk factor that increases long-term risk but is not itself evidence of established malignancy.
• C. This is a risk factor that predisposes to cancer development over time, not a direct sign that cancer is already present.
• D. This symptom is nonspecific and seen in many benign upper gastrointestinal conditions.

A middle-aged woman with cholestatic liver enzymes (disproportionately raised alkaline phosphatase and GGT compared to transaminases), pruritus, fatigue, and a normal biliary tree on ultrasound is classic for primary biliary cholangitis. The diagnosis is confirmed by a positive anti-mitochondrial antibody, which is present in over 90% of cases. The disease predominantly affects women over 40 years old and causes progressive destruction of small intrahepatic bile ducts. Pruritus often precedes jaundice and results from accumulation of bile salts.

• A. Choledocholithiasis would show a dilated common bile duct or stones on ultrasound, which is absent here.
• B. Primary sclerosing cholangitis is more common in young men, often associated with inflammatory bowel disease, and shows beaded strictures on cholangiography rather than a normal duct system.
• D. Autoimmune hepatitis typically presents with a hepatitic pattern (markedly elevated transaminases) rather than a cholestatic one.

In a young patient with neuropsychiatric symptoms, Kayser-Fleischer rings, and low ceruloplasmin, Wilson disease is strongly suspected, and a 24-hour urinary copper excretion is the recommended initial confirmatory test in most guidelines because it is noninvasive and typically elevated above 100 micrograms per 24 hours in symptomatic disease. Liver biopsy with quantitative hepatic copper measurement remains the gold standard but is reserved for cases where noninvasive tests are inconclusive, given its invasiveness. Low ceruloplasmin alone is not fully specific or sensitive, so a confirmatory copper measurement is required before starting chelation therapy. Genetic testing for ATP7B mutations can also support diagnosis but is not the immediate next step when clinical features are already highly suggestive.

• A. Liver biopsy for hepatic copper is more invasive and reserved for cases where noninvasive testing is inconclusive, not the first confirmatory step here.
• C. Alpha-1 antitrypsin level evaluates a different cause of liver disease unrelated to this presentation.
• D. Serum iron and ferritin evaluate hemochromatosis, not Wilson disease.

The combination of markedly elevated ferritin, elevated serum iron, reduced total iron-binding capacity, and a transferrin saturation above 45% indicates iron overload rather than deficiency or inflammation. Hereditary hemochromatosis, most often due to HFE gene mutations, causes reduced hepcidin activity, leading to unregulated intestinal iron absorption and progressive deposition in the liver, pancreas, joints, skin, and heart. The classic triad of skin bronzing, diabetes, and arthropathy affecting the second and third metacarpophalangeal joints reflects this systemic iron deposition. Family history supports an inherited pattern, and genetic testing for HFE mutations or liver biopsy with hepatic iron index can confirm the diagnosis.

• B. Chronic inflammation (anemia of chronic disease) typically shows low serum iron, low transferrin saturation, and normal-to-high ferritin, not this pattern.
• C. Thalassemia minor does not typically cause this degree of iron overload or these clinical features.
• D. Iron deficiency anemia shows low ferritin, low serum iron, and high total iron-binding capacity, which is the opposite of these findings.

The patient has non-alcoholic fatty liver disease associated with obesity, central adiposity, and type 2 diabetes, the most common risk factors for this condition. The cornerstone of management for all patients with NAFLD is lifestyle modification, including gradual weight loss of 7-10% of body weight through caloric restriction and regular physical activity, which has been shown to reduce hepatic steatosis and inflammation. Pharmacologic options such as pioglitazone or vitamin E are considered second-line and are generally reserved for patients with biopsy-proven non-alcoholic steatohepatitis who do not respond to lifestyle measures. Bariatric surgery is considered only after failure of conservative measures in eligible patients with severe obesity.

• A. Pioglitazone is a second-line option considered in biopsy-proven steatohepatitis, not the first step.
• B. Bariatric surgery is reserved for patients who fail lifestyle and medical measures and meet specific body mass index criteria.
• C. Vitamin E is a second-line adjunct for non-diabetic patients with biopsy-proven steatohepatitis, not initial therapy.

A Maddrey discriminant function score of 32 or greater indicates severe alcoholic hepatitis and predicts significant short-term mortality, identifying patients who benefit from corticosteroid therapy such as oral prednisolone, provided active infection or gastrointestinal bleeding has been excluded. This patient's score of 62 confirms severe disease, and infection has already been ruled out by cultures and ascitic fluid analysis, satisfying the safety requirement before starting steroids. Response is typically reassessed at day 7 using the Lille score, which helps decide whether to continue or stop steroid therapy. Supportive care, nutrition, and alcohol cessation counseling remain essential alongside pharmacologic treatment.

• A. N-acetylcysteine is used in acetaminophen-induced liver injury, not alcoholic hepatitis, though it may be used as an adjunct in some protocols, it is not the primary next step here.
• B. Transplantation evaluation is considered in steroid non-responders or specific severe cases, not as the immediate next step before a trial of medical therapy.
• D. Empirical antibiotics are not indicated since infection has already been excluded by cultures and ascitic fluid analysis.

Acute liver failure is defined as the development of coagulopathy, usually an INR of 1.5 or greater, together with hepatic encephalopathy in a patient with no prior history of chronic liver disease, occurring within 26 weeks of the onset of illness. This patient has no underlying liver disease, developed jaundice 3 weeks ago, and now shows coagulopathy and altered mental status, fitting this definition. Her disorientation to place and time with a preserved response to verbal commands and presence of asterixis corresponds to grade II encephalopathy on the West Haven classification, which also includes lethargy and inappropriate behavior. Grade I involves mild confusion and altered sleep pattern without disorientation, while grade III involves marked confusion with somnolence and incoherent speech, and grade IV is coma.

• A. Her encephalopathy is acute, not chronic, and her liver dysfunction is severe, not minimal.
• B. There is no evidence of underlying cirrhosis, and her encephalopathy grade is higher than grade III.
• D. Acute-on-chronic liver failure requires a background of chronic liver disease, which this patient does not have, and her encephalopathy grade is higher than grade I.

Spontaneous bacterial peritonitis is diagnosed by an ascitic fluid absolute neutrophil (polymorphonuclear leukocyte) count of 250 cells/microliter or greater in a patient without a surgical or secondary cause of peritonitis, regardless of culture results. This patient's calculated absolute neutrophil count is 650 multiplied by 0.70, equal to 455 cells/microliter, which exceeds the diagnostic threshold and supports starting empirical antibiotics immediately. Ascitic fluid culture is often negative, around 40% of cases, due to low bacterial density, so a negative or pending culture should not delay treatment when the neutrophil count is elevated. The serum-ascites albumin gradient helps classify the cause of ascites as portal hypertensive but does not diagnose infection.

• B. Total protein helps distinguish ascites causes and predict risk but is not the diagnostic criterion for infection.
• C. The serum-ascites albumin gradient classifies the cause of ascites, confirming portal hypertension, but does not diagnose infection.
• D. Culture is frequently negative in spontaneous bacterial peritonitis and is not required to make the diagnosis or start treatment.

Patients with cirrhosis presenting with acute gastrointestinal variceal bleeding should receive short-term antibiotic prophylaxis, typically intravenous ceftriaxone for up to 7 days, regardless of the presence of ascites or its protein content, because bacterial infection is both a common trigger and a complication of variceal hemorrhage and antibiotics reduce rebleeding and mortality. This differs from prophylaxis based on ascitic fluid protein content, which applies to primary prophylaxis in patients with low ascitic protein (less than 1.5 g/dL) and additional risk factors such as renal or hepatic impairment, typically using norfloxacin, and to secondary prophylaxis after a prior episode of spontaneous bacterial peritonitis. Since this patient's indication for prophylaxis is the acute variceal bleed itself, short-course intravenous antibiotics are indicated now rather than long-term oral prophylaxis.

• A. Rifaximin is used for hepatic encephalopathy prevention, not for spontaneous bacterial peritonitis prophylaxis during variceal bleeding.
• C. Antibiotic prophylaxis is indicated at the time of variceal bleeding regardless of current signs of infection, as it reduces bacterial translocation and mortality.
• D. Lifelong norfloxacin is reserved for secondary prophylaxis after a prior spontaneous bacterial peritonitis episode or long-term primary prophylaxis criteria, not for an acute bleeding episode.

Lactulose is a non-absorbable disaccharide that reaches the colon unchanged, where bacteria ferment it into short-chain fatty acids, lowering luminal pH. This acidic environment converts absorbable ammonia (NH3) into non-absorbable ammonium (NH4+), trapping it in the gut lumen for excretion. It also acts as an osmotic laxative, increasing bowel transit and reducing ammonia absorption time. Hypokalemia and dehydration from diuretics are common precipitants of hepatic encephalopathy because they increase renal ammoniagenesis and reduce hepatic clearance.

• B. Lactulose acts in the gut lumen, not by binding ammonia in the bloodstream.
• C. Its primary site of action is the colon, not the kidney.
• D. Lactulose has no direct effect on hepatic urea cycle enzymes.

Hepatorenal syndrome is a diagnosis of exclusion in cirrhotic patients with ascites, defined by acute kidney injury that fails to improve after withdrawal of diuretics and volume expansion with albumin, in the absence of shock, nephrotoxic drugs, or structural kidney disease. Urinalysis is typically bland, and fractional excretion of sodium is usually low (under 1%) because the physiology is a functional, pre-renal-type injury driven by splanchnic vasodilation and renal vasoconstriction. Red cell casts or heavy proteinuria would suggest an intrinsic glomerular process rather than hepatorenal syndrome. Bilateral small echogenic kidneys suggest chronic kidney disease, not the acute functional renal failure of hepatorenal syndrome.

• A. Small echogenic kidneys indicate chronic structural kidney disease, inconsistent with the acute functional nature of hepatorenal syndrome.
• B. Red cell casts and proteinuria point to intrinsic glomerular disease, not hepatorenal syndrome.
• C. Hepatorenal syndrome typically shows a low fractional excretion of sodium, reflecting avid sodium retention.

The MELD score, calculated from serum bilirubin, creatinine, and INR (with sodium in the MELD-Na variant), was developed specifically to predict short-term (three-month) mortality in patients with cirrhosis and is the standard tool used worldwide for liver transplant organ allocation priority. The Child-Pugh score is useful for general prognosis and surgical risk stratification but relies partly on subjective variables (ascites and encephalopathy grading) and was not designed for organ allocation. The Maddrey discriminant function is used specifically to decide on corticosteroid therapy in severe alcoholic hepatitis. The Glasgow-Blatchford score predicts the need for intervention in acute upper gastrointestinal bleeding, unrelated to transplant prioritization.

• A. The Maddrey discriminant function guides steroid therapy decisions in alcoholic hepatitis, not transplant priority.
• B. The Glasgow-Blatchford score assesses risk in acute gastrointestinal bleeding, unrelated to liver transplant allocation.
• C. Child-Pugh is useful for general prognosis but is not the standard for transplant organ allocation.

Murphy's sign is elicited by placing the examiner's hand below the right costal margin and asking the patient to inhale deeply; a positive sign is abrupt cessation of inspiration due to pain when the inflamed, tender gallbladder descends with diaphragmatic contraction and contacts the palpating fingers. This is a direct, local peritoneal irritation response at the site of inflammation, not a referred or purely reflex phenomenon. The combination of fever, right upper quadrant tenderness, leukocytosis, and ultrasound findings of wall thickening and pericholecystic fluid with gallstones fulfills the diagnostic criteria for acute cholecystitis. Murphy's sign has good sensitivity but is less specific in elderly patients, who may have blunted peritoneal signs.

• A. The sign is due to direct mechanical pain on gallbladder contact, not a vagally mediated bradycardic reflex.
• B. Murphy's sign reflects local peritoneal contact and pain, not phrenic-mediated referred rectus contraction.
• C. This is a local somatic pain response from direct organ palpation, not a spinal visceral-somatic reflex arc.

This patient demonstrates Reynolds' pentad (an extension of Charcot's triad) with fever, jaundice, right upper quadrant pain, hypotension, and altered mental status, indicating severe acute ascending cholangitis with sepsis rather than uncomplicated choledocholithiasis. Charcot's triad (fever, jaundice, right upper quadrant pain) suggests bacterial infection of an obstructed biliary system, distinguishing cholangitis from simple stone obstruction, which typically causes pain and possibly jaundice without fever or systemic toxicity. Isolated right upper quadrant pain is common in biliary colic from stones without infection and is not specific to cholangitis. Elevated bilirubin and alkaline phosphatase reflect cholestasis from any cause of ductal obstruction and are not specific markers of infection by themselves.

• A. Right upper quadrant pain alone is typical of biliary colic from simple stones and does not indicate infection.
• B. Alkaline phosphatase rises with any cholestatic process, including uninfected ductal obstruction, not only infection.
• C. Bilirubin elevation reflects cholestasis generally and is not specific to infectious cholangitis.

This patient has severe (grade III) acute cholangitis according to the Tokyo Guidelines, defined by organ dysfunction (septic shock with hypotension refractory to fluids and altered mental status) in addition to the features of cholangitis. Current guidelines recommend urgent biliary drainage, preferably via endoscopic retrograde cholangiopancreatography, within 24 hours for severe cholangitis, after initial hemodynamic stabilization and antibiotics, since antibiotics alone cannot clear an obstructed, infected biliary system. Open surgical exploration is reserved for cases where endoscopic or percutaneous drainage fails or is unavailable, as it carries higher morbidity in acutely ill patients. Delaying decompression until after discharge risks ongoing sepsis and worsening organ failure, which can be fatal in this high-risk patient.

• B. Open surgery is reserved for failed or unavailable endoscopic/percutaneous drainage, not as first-line therapy.
• C. Antibiotics alone cannot relieve the underlying ductal obstruction driving ongoing sepsis.
• D. Delaying decompression in severe cholangitis risks progressive sepsis and organ failure; urgent drainage is required.

In acute pancreatitis without a clear history of alcohol use and with normal triglycerides and calcium, biliary etiology must be excluded first because gallstones are the most common cause overall. Transabdominal ultrasound is the initial investigation of choice: it is inexpensive, noninvasive, and highly sensitive for detecting gallstones and can suggest bile duct dilation. The elevated transaminases and alkaline phosphatase further support a biliary source. MRCP or ERCP are reserved for cases with suspected choledocholithiasis not resolved by ultrasound or when therapeutic duct clearance is needed.

• A. ERCP is both diagnostic and therapeutic but is invasive and reserved for confirmed or highly suspected obstructing choledocholithiasis.
• C. IgG4 testing is used to evaluate for autoimmune pancreatitis, which is not suggested by this presentation.
• D. MRCP is used when ultrasound is inconclusive or when common bile duct stones are suspected despite a negative ultrasound, not as the first test.

Infected pancreatic necrosis, suggested by gas within the collection, fever, and leukocytosis, requires antibiotics targeting gut flora as initial management. Definitive intervention should follow a step-up approach, starting with percutaneous or endoscopic drainage, with surgical necrosectomy reserved for cases that fail less invasive measures. Intervention is ideally delayed until the necrosis is walled-off, typically around 4 weeks, unless the patient is unstable or deteriorating, which allows the collection to demarcate and reduces complications. This patient is stable, so antibiotics and a planned step-up drainage approach are appropriate rather than emergency surgery.

• B. Open necrosectomy is reserved for cases failing minimally invasive step-up therapy, not first-line management.
• C. Antibiotics should be started before or alongside drainage in infected necrosis to control systemic sepsis.
• D. Infected necrosis requires active intervention with antibiotics and drainage; it will not resolve with supportive care alone.

Primary sclerosing cholangitis is a well-recognized extraintestinal manifestation of inflammatory bowel disease, most strongly associated with ulcerative colitis, and its activity is independent of bowel disease control. The classic MRCP finding is a beaded appearance of multifocal strictures and dilations affecting the intrahepatic and extrahepatic bile ducts, along with a cholestatic liver enzyme pattern. It carries an increased risk of cholangiocarcinoma and colorectal cancer, requiring surveillance. This diagnosis should be suspected in any IBD patient with unexplained cholestatic liver tests, regardless of intestinal disease activity.

• A. Autoimmune hepatitis typically shows a hepatocellular pattern with elevated transaminases and interface hepatitis on biopsy, not a beaded biliary stricture pattern on MRCP.
• B. Gallstone-induced cholangitis would show fever, right upper quadrant pain, and stones or duct dilation on imaging rather than multifocal beaded strictures.
• C. Mesalamine hepatotoxicity is rare and does not produce the classic multifocal biliary stricture pattern seen on MRCP.

Mesalazine (5-ASA) works topically on colonic mucosa by inhibiting cyclooxygenase and lipoxygenase pathways, reducing prostaglandin and leukotriene-mediated inflammation. It is first-line for induction and maintenance of remission in mild-to-moderate ulcerative colitis, especially distal disease where rectal or oral formulations achieve high mucosal concentrations. Anti-TNF biologics and immunomodulators are reserved for moderate-to-severe disease, steroid-dependent or steroid-refractory cases, or when 5-ASA fails. Corticosteroids induce remission in moderate-severe flares but are not used for maintenance due to long-term toxicity.

• A. Azathioprine is a steroid-sparing immunomodulator used for maintenance in steroid-dependent disease, not first-line therapy.
• B. Corticosteroids induce remission in active flares but have no role in maintenance therapy.
• D. Anti-TNF therapy is reserved for moderate-to-severe or refractory disease, not first-line mild distal colitis.

Toxic megacolon is defined by colonic dilation greater than 6 cm on imaging plus systemic toxicity (fever, tachycardia, leukocytosis, anemia, or hypotension), and in this patient it complicates a severe ulcerative colitis flare. Initial management is medical: intravenous corticosteroids, bowel rest, nasogastric decompression if needed, correction of fluid and electrolyte abnormalities, and early surgical consultation because colectomy is required if there is no improvement within 24-72 hours or if perforation occurs. Colonoscopy is contraindicated due to the high risk of perforation. Antimotility agents like loperamide worsen colonic dilation and must be avoided.

• A. Antimotility agents such as loperamide are contraindicated as they can precipitate or worsen toxic megacolon.
• B. Empirical antibiotics for Clostridioides difficile are not the primary step here; the picture is consistent with a severe UC flare requiring steroids, though C. difficile should be excluded by stool testing.
• C. Colonoscopy is contraindicated in toxic megacolon because of the high risk of perforation.

Patients with ulcerative colitis extending beyond the rectum have an increased risk of colorectal cancer that begins to rise after 8-10 years of disease, so surveillance colonoscopy with extensive or targeted biopsies (depending on technique) should start around this time and be repeated every 1-3 years depending on individual risk factors. This patient has no additional risk factors such as primary sclerosing cholangitis or family history, which would otherwise mandate annual surveillance. Average-risk screening intervals and stool-based tests are inadequate because chronic colitis causes field cancerization with flat, often invisible dysplasia that requires direct mucosal inspection and biopsy. CT colonography cannot reliably detect flat dysplastic lesions.

• A. Stool-based testing cannot detect flat dysplasia characteristic of colitis-associated neoplasia.
• B. Average-risk screening intervals underestimate the elevated cancer risk conferred by chronic extensive colitis.
• C. CT colonography lacks the sensitivity to detect flat mucosal dysplasia and does not allow biopsy.

Although a strongly positive tissue transglutaminase IgA antibody with normal total IgA is highly suggestive of celiac disease, current guidelines in adults require confirmation with upper endoscopy and duodenal biopsy (showing villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis) before committing a patient to lifelong dietary restriction. Biopsy should be performed while the patient is still consuming gluten, since a gluten-free diet started beforehand can normalize both serology and histology, obscuring the diagnosis. HLA-DQ2/DQ8 testing has high sensitivity but low specificity and is mainly useful to exclude celiac disease, not to confirm it. Repeating serology adds no diagnostic value when the test is already strongly positive.

• A. The antibody is already strongly positive; repeating it delays diagnosis without added benefit.
• B. Starting a gluten-free diet before biopsy risks normalizing histology and missing the confirmatory diagnosis.
• D. HLA typing is used to exclude celiac disease when negative, not to confirm it, due to low specificity.

Rome IV criteria define irritable bowel syndrome as recurrent abdominal pain occurring on average at least one day per week in the preceding 3 months, associated with two or more of: relation to defecation, change in stool frequency, or change in stool form, with symptom onset at least 6 months before diagnosis. This patient's presentation fits these criteria, and the absence of alarm features (bleeding, weight loss, nocturnal symptoms, abnormal labs) supports a functional diagnosis without need for extensive investigation. Microscopic colitis and inflammatory bowel disease typically present with chronic watery or bloody diarrhea and require colonoscopy with biopsy for diagnosis, not a clinical symptom-based approach. Bile acid diarrhea presents with chronic watery diarrhea rather than a pain-predominant pattern with normal stool between episodes.

• A. Microscopic colitis presents with chronic non-bloody watery diarrhea and requires colonic biopsy for diagnosis, inconsistent with this pain-predominant picture.
• B. Inflammatory bowel disease typically shows alarm features such as bleeding, weight loss, or abnormal inflammatory markers, which are absent here.
• C. Bile acid diarrhea causes chronic watery diarrhea rather than the pain-defecation relationship described.

This patient has two major risk factors for small intestinal bacterial overgrowth: diabetic autonomic neuropathy impairing small bowel motility, and anatomical alteration from Roux-en-Y bypass creating stagnant blind loops. The combination of bloating, flatulence, diarrhea, low B12 (consumed by bacteria) with elevated folate (synthesized by bacteria) is classic for SIBO. The glucose or lactulose hydrogen breath test is the standard noninvasive method, detecting an early rise in breath hydrogen from bacterial fermentation of the substrate in the proximal small bowel; quantitative jejunal aspirate culture is the gold standard but is invasive and less practical. Fecal calprotectin screens for intestinal inflammation seen in IBD, anti-tTG antibody tests for celiac disease, and secretin stimulation testing evaluates pancreatic exocrine function, none of which fit this clinical picture.

• B. Anti-tTG antibody is used for celiac disease, which does not explain the B12/folate pattern or motility risk factors here.
• C. Secretin stimulation testing assesses pancreatic exocrine function, not small bowel bacterial overgrowth.
• D. Fecal calprotectin detects intestinal inflammation as in IBD, not bacterial overgrowth.

Most cases of acute watery diarrhea in healthy adults are self-limited, viral or non-invasive bacterial in origin, and respond to oral rehydration and supportive care alone. Empirical antibiotics are not indicated in mild-to-moderate watery diarrhea without features suggesting invasive bacterial infection such as high fever, bloody stools, fecal leukocytes, severe systemic toxicity, immunosuppression, or recent travel to areas with high risk of specific treatable pathogens. Antibiotics are reserved for dysentery, suspected shigellosis, cholera, or infection in high-risk hosts (immunocompromised, severe systemic illness, or hospitalization needed). This patient has no bloody stool, no fecal leukocytes, and is hemodynamically stable with mild illness, making supportive care the correct approach.

• A. The patient is hemodynamically stable and tolerating oral fluids, so IV antibiotics and admission are unwarranted.
• C. Metronidazole targets specific protozoal or anaerobic infections, not empirical treatment of undifferentiated watery diarrhea.
• D. Empirical fluoroquinolone therapy is unnecessary in mild non-bloody, non-invasive diarrhea in an otherwise healthy patient.

This patient has a first episode of non-severe to moderate C. difficile infection (CDI), and current IDSA/ACG guidelines recommend oral vancomycin (125 mg four times daily for 10 days) or oral fidaxomicin as first-line therapy, replacing metronidazole as the preferred agent even for mild disease. Vancomycin acts locally in the gut lumen by inhibiting bacterial cell wall synthesis, achieving high colonic concentrations with minimal systemic absorption. Metronidazole is now reserved for settings where vancomycin or fidaxomicin are unavailable, due to inferior clinical response rates. Oral administration is essential because intravenous vancomycin does not reach adequate concentrations in the colon.

• B. Rifaximin is not recommended as primary therapy and is sometimes used to prevent recurrence, not treat the acute episode.
• C. Intravenous metronidazole does not achieve adequate luminal concentration and is not preferred first-line therapy.
• D. Metronidazole is no longer first-line due to lower cure rates compared with vancomycin or fidaxomicin.

This patient has uncomplicated acute diverticulitis (no abscess, perforation, or systemic sepsis) and is hemodynamically stable with tolerable oral intake, making outpatient management with oral antibiotics appropriate per current guidelines. A short course of a low-residue diet is advised during the acute symptomatic phase, with gradual return to a high-fiber diet after resolution to reduce recurrence. Colonoscopy is deferred for 6-8 weeks after resolution of the acute episode to exclude malignancy, not performed urgently during active inflammation due to perforation risk. Hospitalization is reserved for patients with complicated diverticulitis, significant comorbidities, immunosuppression, or inability to tolerate oral intake.

• A. Colonoscopy during acute diverticulitis carries a perforation risk and should be delayed 6-8 weeks until inflammation resolves.
• B. Inpatient IV antibiotics are reserved for complicated diverticulitis or patients unable to tolerate oral intake, not this stable uncomplicated case.
• D. Emergency surgery is not indicated for uncomplicated diverticulitis without abscess, perforation, or peritonitis.

Classic migratory periumbilical-to-right-lower-quadrant pain, anorexia, low-grade fever, leukocytosis, and a positive psoas sign with a normal pelvic examination and negative pregnancy test strongly favor acute appendicitis. Ovarian torsion typically presents with sudden severe unilateral pelvic pain and an abnormal ultrasound showing an enlarged ovary with absent or reduced Doppler flow, which is excluded here. Ruptured ectopic pregnancy is ruled out by the negative pregnancy test. Mittelschmerz is a mid-cycle, self-limited pain without fever or significant leukocytosis, inconsistent with this presentation.

• A. Mittelschmerz does not cause fever, leukocytosis, or a positive psoas sign.
• B. Ectopic pregnancy is excluded by the negative urine pregnancy test.
• C. Ovarian torsion was excluded by a normal pelvic ultrasound showing no ovarian abnormality.

Sharp, severe pain during and after defecation lasting minutes, combined with a visible posterior midline linear tear at the anal verge, is classic for an anal fissure, most commonly caused by passage of hard stool leading to trauma and sphincter spasm. Internal hemorrhoids typically cause painless bleeding unless thrombosed or prolapsed, and do not produce a visible linear tear. Colorectal carcinoma more often presents with painless bleeding, altered bowel habit, or weight loss in an older patient, and is less likely at age 29 without alarm features. Rectal prolapse presents as a protruding mass with straining rather than a linear mucosal tear and acute postdefecation pain.

• B. Internal hemorrhoids typically cause painless bleeding and would not produce a visible linear tear at the anal verge.
• C. Rectal prolapse presents as a protruding rectal mass, not a linear anal tear with sharp postdefecation pain.
• D. Colorectal carcinoma usually presents with painless bleeding and alarm features such as weight loss, which are absent here.

Valid informed consent requires disclosure of the nature of the procedure, its material risks (such as bleeding, perforation, and sedation-related complications), and reasonably foreseeable interventions that may occur during the same procedure, such as polypectomy if a polyp is encountered. This allows the patient to make an autonomous decision about the full scope of the planned intervention rather than being surprised mid-procedure. Obtaining a separate consent during sedation is impractical and undermines patient autonomy, since the patient cannot meaningfully participate in decision-making while sedated. The responsibility for obtaining informed consent rests with the physician performing the procedure, not ancillary staff, and a signature alone without adequate disclosure does not constitute valid consent.

• A. A signature without proper disclosure of risks and expected findings does not meet the standard for valid informed consent.
• B. The performing physician, not nursing staff, bears responsibility for ensuring adequate informed consent discussion.
• C. Once sedated, the patient cannot provide valid consent for additional interventions, so foreseeable procedures like polypectomy must be discussed beforehand.

A competent adult patient has the right to be informed of findings from her own procedure, and the physician's primary duty of disclosure is to the patient, not to family members who have not been authorized to make decisions on her behalf. Family requests to withhold a diagnosis, even when well-intentioned, do not override patient autonomy unless the patient herself has previously and explicitly waived the right to know or lacks decision-making capacity. Disclosure should be done compassionately, in a private setting, using clear language, and with psychological support offered given the anxiety-provoking nature of a likely malignancy diagnosis. Referring the decision to an ethics committee is unnecessary here since there is no genuine ethical dilemma: the patient has capacity and has not opted out of being informed.

• B. Indefinite non-disclosure denies the patient timely information needed for further management and violates the duty of honesty.
• C. Withholding significant medical information from a competent patient at a family member's request violates patient autonomy and the right to know one's own diagnosis.
• D. This is a matter of routine physician-patient communication and does not require ethics committee referral, since the patient's right to disclosure is clear.

In a patient younger than 60 years with typical reflux symptoms (heartburn, regurgitation) and no alarm features, GERD can be diagnosed clinically and treated empirically with a PPI without further investigation. Symptom improvement with PPI therapy supports the diagnosis. Endoscopy and other investigations are reserved for patients with alarm features, atypical symptoms, or those who fail empirical therapy. This approach is cost-effective and avoids unnecessary invasive procedures in low-risk patients.

• A. pH monitoring is reserved for atypical symptoms or before anti-reflux surgery, not for initial diagnosis.
• B. Barium esophagram has low sensitivity for reflux disease and is not the recommended initial test.
• C. Endoscopy is unnecessary as first step in a young patient with typical symptoms and no alarm features.

This patient has alarm features including dysphagia, unintentional weight loss, and age over 55 years, which mandate prompt upper endoscopy to rule out malignancy or other structural esophageal disease. Empirical PPI therapy without endoscopic evaluation would risk delaying diagnosis of esophageal or gastric cancer. Alarm features identified by international guidelines (ACG, SCFHS-aligned protocols) include dysphagia, odynophagia, weight loss, GI bleeding, anemia, persistent vomiting, and age over 55 with new-onset symptoms. Endoscopy allows direct visualization and biopsy if a mass or stricture is found.

• A. H. pylori testing does not address the need to exclude malignancy causing dysphagia and weight loss.
• B. Empirical therapy is inappropriate when alarm features such as dysphagia and weight loss are present.
• C. Manometry assesses motility disorders but is not the first step when malignancy must be excluded.

Barrett esophagus is the replacement of normal squamous epithelium with columnar epithelium containing intestinal metaplasia (goblet cells), occurring as a complication of chronic GERD. It is a premalignant condition that confers an increased risk of progression through dysplasia to esophageal adenocarcinoma, which is why patients require periodic surveillance endoscopy with biopsies. The risk of malignant transformation correlates with the degree of dysplasia found on biopsy. Squamous cell carcinoma is not related to Barrett metaplasia, as it arises from the native squamous epithelium and is linked to different risk factors such as smoking and alcohol.

• A. Achalasia is a motility disorder unrelated to intestinal metaplasia from chronic reflux.
• B. Barrett esophagus, being columnar metaplasia, predisposes to adenocarcinoma, not squamous cell carcinoma.
• D. Eosinophilic esophagitis is a distinct allergic/immune condition, not a consequence of Barrett metaplasia.

Esophageal manometry is the gold-standard confirmatory test for achalasia, demonstrating the characteristic findings of incomplete or absent relaxation of the lower esophageal sphincter and absence of normal peristalsis in the esophageal body. While barium esophagram showing the bird-beak sign and endoscopy excluding pseudoachalasia (mechanical obstruction) support the diagnosis, manometry is required to confirm the motor abnormality. High-resolution manometry also allows subtyping of achalasia (I, II, III), which guides treatment choice between pneumatic dilation, Heller myotomy, or peroral endoscopic myotomy.

• B. pH monitoring assesses acid reflux and is not used to diagnose achalasia.
• C. Endoscopy has already excluded a mechanical cause; repeating it adds no diagnostic value for confirming achalasia.
• D. CT chest may be used to exclude secondary causes of pseudoachalasia but does not confirm the primary motor diagnosis.

Eosinophilic esophagitis (EoE) is a chronic immune/antigen-mediated esophageal disease, common in young patients with atopic history, presenting with dysphagia and recurrent food impaction. Endoscopic findings of concentric rings (trachealization), longitudinal furrows, and whitish exudates are suggestive but not diagnostic. Diagnosis requires esophageal biopsies from at least two levels (proximal and distal) showing eosinophilic infiltration of at least 15 eosinophils per high-power field, after excluding other causes of esophageal eosinophilia such as GERD. Treatment includes proton pump inhibitors, topical corticosteroids, and dietary elimination.

• B. Manometry evaluates motility disorders and is not used to diagnose EoE.
• C. pH monitoring helps distinguish GERD but does not establish the histologic diagnosis of EoE.
• D. Serum IgE is nonspecific and not a diagnostic criterion for EoE.

In hemodynamically unstable patients with acute upper GI bleeding, airway protection and restoration of intravascular volume with crystalloid take priority over any diagnostic or specific pharmacologic intervention. Fluid resuscitation corrects shock and buys time for cross-matching blood and arranging endoscopy. Endoscopy, though important, should follow hemodynamic stabilization, typically within 24 hours (sooner if still unstable after resuscitation). Proton pump inhibitors and blood products are adjuncts given after or during initial volume resuscitation, not before it.

• B. FFP is reserved for documented coagulopathy and is not the first priority before volume resuscitation.
• C. Endoscopy is essential but must follow initial hemodynamic stabilization, not precede it in an unstable patient.
• D. PPI therapy is appropriate adjunctive treatment but does not address the immediate hypovolemic shock.

The Glasgow-Blatchford score (GBS) stratifies patients with upper GI bleeding by risk of needing intervention or transfusion, incorporating blood urea nitrogen, hemoglobin, systolic blood pressure, heart rate, and clinical features such as syncope or melena. A score of 0 or 1 identifies very low-risk patients who can be safely managed as outpatients without urgent hospitalization or endoscopy. Higher scores predict the need for transfusion, endoscopic intervention, or death, guiding admission decisions. This patient's normal vital signs, low urea, and preserved hemoglobin confirm very low risk, so outpatient management with early follow-up endoscopy is appropriate.

• B. ICU admission is unwarranted given hemodynamic stability and a minimal risk score.
• C. Admission for IV PPI and inpatient endoscopy is reserved for patients with intermediate to high Glasgow-Blatchford scores, not a score of 0.
• D. Urgent endoscopy within 6 hours is reserved for high-risk or unstable presentations, not a very low-risk score.

In suspected variceal hemorrhage, vasoactive drugs such as octreotide or terlipressin should be started as soon as the diagnosis is suspected, even before confirmatory endoscopy, because they reduce splanchnic blood flow and portal pressure, controlling bleeding and improving outcomes. Short-term antibiotic prophylaxis (commonly a third-generation cephalosporin) is also indicated in all cirrhotic patients with GI bleeding, since it reduces the risk of bacterial infection and spontaneous bacterial peritonitis and improves survival. Propranolol is used for secondary prophylaxis after bleeding has stopped, not during active hemorrhage. Heparin and tranexamic acid have no established role in acute variceal bleeding and may worsen outcomes.

• A. Propranolol is a non-selective beta-blocker used for secondary prevention once bleeding is controlled, not during active hemorrhage; vitamin K has no proven role here.
• C. Tranexamic acid is not recommended in variceal bleeding and may increase thrombotic risk; rifaximin is used for encephalopathy, not acute bleeding.
• D. Heparin is contraindicated in active bleeding; lactulose treats hepatic encephalopathy, not active hemorrhage.

For hemodynamically stable patients with acute non-variceal upper GI bleeding, current guidelines recommend performing upper endoscopy within 24 hours of presentation after adequate resuscitation. This timing allows identification of the bleeding source, risk stratification using endoscopic stigmata, and endoscopic hemostasis if needed, while avoiding the increased risks associated with very early (within 6 hours) endoscopy in stable patients, which has not shown outcome benefit and may be technically harder due to blood in the stomach. Delaying beyond 24 hours increases the risk of rebleeding and mortality. Endoscopy should not be withheld until instability occurs, since early diagnosis guides therapy and discharge planning.

• A. Waiting 72 hours unnecessarily delays diagnosis and treatment, increasing risk of rebleeding.
• B. Withholding endoscopy until instability develops risks missing a treatable lesion and delays appropriate hemostatic therapy.
• C. Endoscopy within 6 hours is reserved for high-risk or unstable patients and offers no proven benefit over 24-hour endoscopy in stable patients.

Isolated positivity for anti-HBs, with negative HBsAg and negative anti-HBc (both total and IgM), is the classic serologic signature of immunity acquired through vaccination rather than natural infection. Vaccination induces antibody only against the surface antigen, since no core antigen is involved, so anti-HBc remains negative. In contrast, resolved natural infection produces positive anti-HBc (IgG) alongside anti-HBs. Acute infection would show a positive IgM anti-HBc, and chronic infection would show persistently positive HBsAg. This distinction is clinically important for confirming vaccine-induced immunity versus past natural exposure.

• A. Acute infection in the window period shows positive IgM anti-HBc with negative HBsAg, not the pattern described.
• B. Resolved natural infection requires a positive anti-HBc (IgG), which is absent here.
• C. Chronic infection requires persistently positive HBsAg, which is negative in this patient.

This patient has HBeAg-positive chronic hepatitis B with high viral load and persistently elevated ALT, indicating active liver inflammation and ongoing hepatocyte damage, which meets criteria for initiating antiviral therapy (such as entecavir or tenofovir) per major guidelines. The immune-tolerant phase, by contrast, features high HBV DNA but normal ALT and minimal inflammation, not requiring immediate treatment. HBeAg-negative chronic hepatitis B would show negative HBeAg with positive anti-HBe, a different phase than described here. The inactive carrier state shows low or undetectable HBV DNA and normal ALT, which does not match this patient's active, elevated markers.

• B. The inactive carrier state requires low/undetectable HBV DNA and normal ALT, inconsistent with this patient's findings.
• C. This patient is HBeAg-positive, not HBeAg-negative, which describes a different serologic phase.
• D. The immune-tolerant phase requires normal ALT, whereas this patient has persistently elevated ALT indicating active liver injury.

A positive anti-HCV antibody with detectable HCV RNA confirms active hepatitis C infection requiring treatment. Current guidelines recommend oral direct-acting antivirals (DAAs) such as sofosbuvir-velpatasvir or glecaprevir-pibrentasvir for essentially all patients with chronic hepatitis C regardless of fibrosis stage, achieving sustained virologic response rates above 95% with short treatment courses and minimal side effects. Interferon-based regimens have been abandoned due to poor tolerability and inferior efficacy compared to DAAs. Deferring treatment until cirrhosis develops is inappropriate, since early treatment prevents progression to fibrosis and hepatocellular carcinoma; tenofovir is an antiviral used for hepatitis B, not hepatitis C.

• A. Treatment should be initiated promptly in essentially all chronic HCV patients, not deferred until cirrhosis develops.
• B. Interferon-based regimens are outdated, poorly tolerated, and inferior to DAAs, and are no longer first-line therapy.
• D. Tenofovir is used for hepatitis B infection and has no antiviral activity against hepatitis C.

The clinical picture of a young woman with fatigue, arthralgia, markedly elevated transaminases, hyperbilirubinemia, elevated IgG, and negative viral serologies is highly suggestive of autoimmune hepatitis. The diagnosis is supported by positive autoantibodies, most commonly antinuclear antibody (ANA) and anti-smooth muscle antibody (ASMA) in type 1 autoimmune hepatitis, which is the most common form, especially in young women. Anti-mitochondrial antibody with elevated alkaline phosphatase would instead suggest primary biliary cholangitis, a predominantly cholestatic disease. Positive hepatitis B surface antigen would indicate viral hepatitis, already excluded by negative serologies, and ceruloplasmin findings relate to Wilson disease, which typically presents differently and with low ceruloplasmin, not elevated.

• A. Hepatitis B surface antigen positivity would indicate viral hepatitis, which has already been excluded by negative serologies.
• B. Anti-mitochondrial antibody with elevated alkaline phosphatase is characteristic of primary biliary cholangitis, a cholestatic disease, not autoimmune hepatitis.
• C. Wilson disease typically shows low, not elevated, serum ceruloplasmin, and presents differently from this hepatitic picture.

Transabdominal ultrasound is the first-line imaging modality for suspected gallstone disease because it is widely available, inexpensive, and has high sensitivity and specificity for detecting gallstones, gallbladder wall thickening, and pericholecystic fluid, without exposing the patient to ionizing radiation. This is especially important in a young woman of reproductive age, where minimizing radiation exposure follows the as-low-as-reasonably-achievable (ALARA) principle. CT and HIDA scans are reserved for equivocal cases or when complications such as choledocholithiasis or acute cholecystitis are suspected but not confirmed on ultrasound. Ultrasound also allows rapid bedside assessment and can be repeated without risk.

• A. Contrast CT carries radiation and contrast-related risks and is not the first-line test for uncomplicated biliary colic.
• B. CT exposes the patient to unnecessary ionizing radiation and is less sensitive than ultrasound for detecting gallstones.
• D. HIDA scan is reserved for cases where acute cholecystitis is suspected but ultrasound findings are inconclusive, not as an initial test.